Post-market Clinical Follow-up Study of NEMOST V2
Key facts
- Who runs it
- EUROS
- Where
- France5 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 140 people, planned
- Started
- 19 Dec 2025
- Expected to end
- 19 Dec 2033
- Type of study
- Interventional
- Treatments tested
- NEMOST V2 growing domino
- Record updated
- 11 February 2026
Who can take part
- Age
- 5 years to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Idiopathic, congenital, neuromuscular, or syndromic scoliosis : Progressive spinal deformity not managed by orthopedic treatment, and requiring primary surgical intervention
- The patient, as well as their parents or legal guardians, are informed of the participation in the study
- Patients aged from 5 to 17 yeas old, excepted the one who still have a potential for growth
Who cannot take part
- acute or chronic, local or systemic infections
- allergy or intolerance to implanted materials
- insufficiency or absence of tissue coverage. The NEMOST implant should not be used in a spine that has already been instrumented or fused
- signs of local inflammation
- non-reducible scoliosis
- pathological obesity
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 5 and 17 years old?
This trial is currently available in France.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The NEMOST spinal implant is a growth domino intended for the surgical treatment of progressive scoliosis in children.
Read full original descriptionShow less
As part of post-market surveillance, EUROS is conducting a retrospective and prospective study to collect clinical and radiological data on the NEMOST growth domino.
Retrospective and prospective multicenter post-market surveillance clinical study.
This study is interventional, non-randomized, and uncontrolled. The primary objective of this clinical study is to monitor complications related to the NEMOST growth domino during a 5-year postoperative follow-up in patients treated for progressive scoliosis in children.
The secondary objective of this clinical study is to monitor the performance of the NEMOST growth domino during a 5-year postoperative follow-up in patients treated for progressive scoliosis in children.
The study will include 140 patients.
The group in the trial
- NEMOST V2Treatment being tested
Treatment: NEMOST V2 growing domino
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Post-market Clinical Follow-up Study of NEMOST V2 Growing Domino
- Criteria questions
- Built from NCT07403084, who can take part
- Record updated
- 11 February 2026